Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Amylyx Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Amylyx PharmaceuticalsDie Umsatzerlöse des Unternehmens werden voraussichtlich um 81.5% pro Jahr zurückgehen, während die jährlichen Gewinne voraussichtlich um 16.4% pro Jahr wachsen werden. Der Gewinn pro Aktie wird voraussichtlich um 19.8% pro Jahr wachsen.

Wichtige Informationen

16.4%

Wachstumsrate der Gewinne

19.8%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.8%
Wachstumsrate der Einnahmen	-81.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	18 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Mar 16

Recent updates

Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Apr 25

Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

Mar 12

An ALS Drug Fails Again

Mar 09

Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications

Feb 23

Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Feb 23

Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

Nov 10

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Sep 24

This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

May 16

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Apr 20

Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Mar 16

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans

Dec 19

Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share

Oct 07

Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis

Sep 30

Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing

Sep 08

Amylyx plunges 28% after FDA briefing documents on ALS drug

Sep 02

We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

Aug 29

Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01

Aug 11

Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada

Jul 29

Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates

Jul 18

Amylyx: Thoughts Ahead Of September 29 PDUFA In Amyotrophic Lateral Sclerosis

Jul 04

Amylyx Pharmaceuticals: Share Price Bump On Canada Approval For ALS Drug May Not Last

Jun 17

We're Keeping An Eye On Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

May 07

Amylyx: Crucial Advisory Committee Meet Tomorrow, Approval Chancy

Mar 29

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:AMLX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	0	-79	233	N/A	5
12/31/2025	N/A	-93	174	N/A	6
12/31/2024	94	-183	112	N/A	6
3/31/2024	398	-71	15	17	N/A
12/31/2023	381	49	11	12	N/A
9/30/2023	294	2	-53	-51	N/A
6/30/2023	192	-73	-91	-89	N/A
3/31/2023	94	-149	-147	-144	N/A
12/31/2022	22	-198	-182	-180	N/A
9/30/2022	0	-184	-161	-158	N/A
6/30/2022	0	-153	-138	-136	N/A
3/31/2022	0	-121	-103	-103	N/A
12/31/2021	0	-88	-75	-75	N/A
9/30/2021	1	-68	-56	-55	N/A
12/31/2020	1	-42	-37	-37	N/A
12/31/2019	1	-14	-11	-11	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AMLX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: AMLX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: AMLX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: AMLXDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-81.5% pro Jahr).

Hohe Wachstumseinnahmen: AMLXDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-81.5% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von AMLX in 3 Jahren voraussichtlich hoch sein wird

Amylyx Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 45%

Consensus revenue estimates fall by 19%

Consensus EPS estimates fall by 54%

Price target decreased by 17% to US$39.40

Forecast breakeven date moved forward to 2023

Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Recent updates

New minor risk - Profitability

Investor sentiment improves as stock rises 15%

Amylyx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024

Amylyx Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Investor sentiment deteriorates as stock falls 20%

Amylyx Pharmaceuticals Announces Interim Data from Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

Consensus revenue estimates fall by 45%

Amylyx Pharmaceuticals, Inc. Announces Formal Intention to Remove Relyvrio/Albriza from the Market

New major risk - Revenue and earnings growth

Amylyx Pharmaceuticals, Inc. Appoints Bernhardt Zeiher to Its Board of Directors

Investor sentiment deteriorates as stock falls 83%

Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

Rosen Law Firm Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Consensus revenue estimates fall by 19%

An ALS Drug Fails Again

Amylyx Pharmaceuticals, Inc. Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

Investor sentiment improves as stock rises 28%

Consensus EPS estimates fall by 54%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications

Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Amylyx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Robbins Geller Rudman & Dowd LLP Announces Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc

Robbins Geller Rudman & Dowd LLP Announces Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc

Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 Orion Study of Amx0035 in Progressive Supranuclear Palsy (Psp)

Amylyx Pharmaceuticals, Inc. Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS

Amylyx Pharmaceuticals Appoints Camille L. Bedrosian as Chief Medical Officer

Price target decreased by 17% to US$39.40

Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

New minor risk - Share price stability

Amylyx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Amylyx Pharmaceuticals, Inc. Announces to Present Clinical Trial Design of ORION, Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy, at Neuro2023 PSP and CBD International Research Symposium

Amylyx Pharmaceuticals, Inc. Receives Negative Chmp Opinion on Its Marketing Authorisation Application for Amx0035 for the Treatment of Als in the European Union Following Re-Examination Process

Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing Centaur to Historical Clinical Trial Control

Amylyx Pharmaceuticals Provides Update on Acces Compassionnel for AMX0035 in France

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Amylyx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Amylyx Pharmaceuticals Canada Enters into Product Listing Agreement with Quebec for the Public Reimbursement of Albriza

Amylyx Pharmaceuticals Canada Enters into Product Listing Agreement with Ontario for Public Reimbursement of ALBRIOZA Through Ontario Drug Benefit Program

Amylyx Pharmaceuticals, Inc. Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union

Amylyx Pharmaceuticals, Inc. Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA for the Treatment of ALS

Amylyx Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union

Insider notifies of intention to sell stock

This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

Amylyx Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Insider notifies of intention to sell stock

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Forecast breakeven date moved forward to 2023

Co-Founder notifies of intention to sell stock

Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Consensus revenue estimates increase by 41%

Amylyx Pharmaceuticals, Inc. Announces Completion of Enrollment in Global Phase 3 Phoenix Trial of AMX0035 in ALS

Co-Founder notifies of intention to sell stock

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans

Amylyx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Amylyx Pharmaceuticals, Inc. Announces Resignation of Isaac Cheng as Board of Directors

Consensus forecasts updated

Forecast breakeven date moved forward to 2023

Consensus forecasts updated

Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share

Consensus forecasts updated

No longer forecast to breakeven

Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis

Amylyx Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approval of RELYVRIO for the Treatment of ALS

Amylyx Pharmaceuticals, Inc. Announces Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035 Compared to Individual Compounds

Amylyx Pharmaceuticals, Inc. Announces FDA Advisory Committee Supports Approval of Amx0035 for the Treatment of ALS

Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing